Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Landgren Website

C. Ola Landgren, M.D., Ph.D.

Portait Photo of C. Ola Landgren
Lymphoid Malignancies Branch
Senior Investigator
Center for Cancer Research
National Cancer Institute
Bulding 10, Room 13N240
Bethesda, MD 20892-1906
Phone:  
301-496-0670
Fax:  
301-402-0172
E-Mail:  
landgreo@mail.nih.gov

Landgren's Video Cast

Produced and edited by Natalie Giannosa

Biography

Dr. Landgren received his M.D. in 1995 from the Karolinska Institute (Stockholm, Sweden). Following clinical training as a hematology/internal medicine specialist physician and receipt of a Ph.D. focusing on diagnostics and prognostics in Hodgkin lymphoma (2002) at Karolinska Institute in Sweden, he worked as an attending physician and conducted clinical research on lymphoproliferative malignancies and related precursors. In 2004, he came to the National Cancer Institute, Genetic Epidemiology Branch, DCEG, where he worked as an Investigator before he joined the Medicial Oncology Branch.

Dr. Landgren's major research interests are in the treatment, causation, diagnostics and prognostics, and natural history of multiple myeloma and its precursor condition, monoclonal gammopathy of undetermined significance (MGUS). He also studies related hematologic malignancies and their precursors states (including chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis (MBL); Waldenstrom's macroglobulinemia and IgM MGUS), as well as myeloproliferative neoplasms. His research focuses on treatment-, host-, disease-, and immune-related factors in the pathway from precursor to full-blown malignancy, and their relation to outcome.

Research

Dr. Landgren's research interests include:

- Examination of novel therapies for multiple myeloma and its precursor states

- Identification of predictors for progression; from precursor to malignancy, and outcome

- Definition of the roles for infectious antigens, inflammation, chronic immune stimulation, and immune modulation in hematopoietic carcinogenesis

- Assessment and definition of host- and disease-related diagnostic/prognostic markers

This page was last updated on 10/28/2013.